FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions relates to oncology and pharmacy. Disclosed are a method of treating associated non-alcoholic steatohepatitis (NASH-associated) liver cancer involving administering a pharmaceutically effective amount of 4-[(1S)-1-({[5-chloro-2-(3-fluorophenoxy)pyridin-3-yl]carbonyl}amino)ethyl]benzoic acid or its salts (embodiments), use of said compound or salt thereof for treating NASH-associated liver cancer and use thereof for producing a medicament for the same purpose.
EFFECT: technical result: compound (or its salt) inhibits the development of obesity-related NASH-associated liver cancer, while re-activating anti-tumour immunity in the microenvironment of the cancer, in particular reduces the population of immune suppressing cells Treg (Foxp3+) in tumour tissue.
12 cl, 8 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| USE OF EP4 RECEPTOR ANTAGONISTS FOR TREATMENT OF NASH-ASSOCIATED LIVER CANCER | 2017 |
|
RU2762193C2 |
| COMBINED THERAPY FOR CANCER TREATMENT | 2015 |
|
RU2708374C2 |
| NOVEL APPROACH TO CANCER TREATMENT USING IMMUNOMODULATION | 2016 |
|
RU2817047C2 |
| NEW APPROACH TO TREATING CANCER WITH APPLICATION OF IMMUNOMODULATION | 2016 |
|
RU2711380C2 |
| TYPES OF COMBINATION THERAPY FOR TREATING CANCER | 2021 |
|
RU2816314C1 |
| BISPECIFIC ANTIBODIES TO CD25 AND Fc GAMMA-RECEPTOR FOR ELIMINATION OF TUMOR-SPECIFIC CELLS | 2017 |
|
RU2759970C2 |
| THIOCARBAMATE DERIVATIVES AS A2A INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS THEREOF WITH ANTICANCER AGENTS | 2019 |
|
RU2824502C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
| ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR | 2018 |
|
RU2740713C1 |
